Shares of Allogene Therapeutics Inc (NASDAQ:ALLO) have been assigned an average rating of “Buy” from the thirteen analysts that are currently covering the stock, MarketBeat.com reports. Five equities research analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $36.22.
Several equities research analysts recently weighed in on ALLO shares. Guggenheim started coverage on Allogene Therapeutics in a research note on Thursday, May 30th. They set a “neutral” rating for the company. Roth Capital started coverage on Allogene Therapeutics in a research note on Wednesday, June 5th. They set a “neutral” rating and a $26.00 target price for the company. Oppenheimer started coverage on Allogene Therapeutics in a research note on Friday, May 3rd. They set an “outperform” rating and a $45.00 target price for the company. JPMorgan Chase & Co. restated a “hold” rating and set a $29.00 target price on shares of Allogene Therapeutics in a research note on Sunday, August 11th. Finally, Zacks Investment Research cut Allogene Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, August 12th.
In other news, insider Alison Moore sold 48,827 shares of the company’s stock in a transaction that occurred on Tuesday, July 30th. The stock was sold at an average price of $29.44, for a total transaction of $1,437,466.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 36.50% of the stock is owned by corporate insiders.
Several institutional investors have recently added to or reduced their stakes in ALLO. Barclays PLC acquired a new position in Allogene Therapeutics during the fourth quarter worth $27,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Allogene Therapeutics during the second quarter worth $65,000. Bank of Montreal Can acquired a new position in Allogene Therapeutics during the second quarter worth $87,000. Legal & General Group Plc acquired a new position in Allogene Therapeutics during the fourth quarter worth $89,000. Finally, BNP Paribas Arbitrage SA acquired a new position in Allogene Therapeutics during the second quarter worth $92,000. Institutional investors and hedge funds own 51.30% of the company’s stock.
ALLO stock traded down $0.04 during trading on Friday, hitting $26.27. 476,400 shares of the company’s stock were exchanged, compared to its average volume of 340,459. The business has a 50-day moving average price of $28.30 and a two-hundred day moving average price of $28.43. The stock has a market capitalization of $3.36 billion and a price-to-earnings ratio of -3.99. Allogene Therapeutics has a 52-week low of $21.67 and a 52-week high of $35.55. The company has a current ratio of 13.46, a quick ratio of 13.46 and a debt-to-equity ratio of 0.05.
Allogene Therapeutics (NASDAQ:ALLO) last posted its earnings results on Wednesday, August 7th. The company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.06. On average, equities research analysts anticipate that Allogene Therapeutics will post -1.94 earnings per share for the current fiscal year.
About Allogene Therapeutics
Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; and ALLO-501, an allogeneic CAR T cell product candidate targeting CD19 to treat R/R non-Hodgkin lymphoma.
Recommended Story: How to find the components of the quick ratio
Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.